Sign up USA
Proactive Investors - Run By Investors For Investors

ImmunoPrecise Antibodies set to buy ModiQuest in C$10.5mln deal

The deal allows IPA to become a single source provider of services across the full antibody discovery value chain, the firm told investors.
ImmunoPrecise Antibodies set to buy ModiQuest in C$10.5mln deal
IPA develops antibodies to support research and development programs

ImmunoPrecise Antibodies Ltd (CVE:IPA, OTC PINK:IPATF) is set to buy ModiQuest Research BV in a C$10.57mln deal, which bolsters its global acquisition strategy and will add to both revenue and earnings, it said.

It allows IPA to become a single source provider of services across the full antibody discovery value chain, it told investors.

In simple terms, IPA develops antibodies to support research and development programs at pharmaceutical and biotechnology companies, as well as academic research labs.

Targetting antigens..

Antibodies  can target molecules, or antigens. They are produced by the immune  system to help stop intruders from harming the body.

This acquisition will enhance the firm's capacity for generating human antibodies, it said.

Privately-held ModiQuest, based in the Netherlands, can generate very large panels of monoclonal antibodies from various backgrounds including mouse, rat, rabbit, chicken, llama and human

ModiQuest serves clients in Europe, the US, Asia and Russia and during 2016, it posted revenues of €2,009,374 (CAD $3,037,249) and earnings of €671,799 (CAD $1,015,451).

"In acquiring ModiQuest Research B.V, IPA becomes a leading integrated antibody solutions company with global reach," said Dr James Kuo,  chairman and interim president of the company.

A binding letter of intent..

Under a binding letter of intent, the  parties have agreed to negotiate a definitive agreement, whereby IPA will acquire all ModiQuest shares for C$10.57mln, of which C$3.775mln will be paid in cash on closing.

Also, C$3.775mln  will be satisfied by issuing around 6.6mln shares on closing, and C$2mln in deferred payments over three years.

The deferred payments will be made in three equal installments of cash and equity totaling (C$$1,006,665) on each anniversary date following closing of the transaction.

The parties will be entitled to carry out due diligence of each other until February 15 next year, and if satisfied, will  enter a definitive agreement by February 28.

Shares added over 5% to C$0.60 each..

View full IPA profile View Profile

Immunoprecise Antibodies Ltd Timeline

Related Articles

consumer health segment overview
September 16 2018
The company sells clinically validated anti-ageing products for hair, skin and body.
Drug discovery
April 04 2018
In the group’s 2017 results statement at the end of March, Ray Barlow - who took over as CEO on 6 April 2017 - commented: “We are now focused on the right activities"
September 28 2018
The biotech group revealed it had brought in $9.1mln via an oversubscribed placing

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume this write-up may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Copyright ©, 2018. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use